STAT3 and nasopharyngeal carcinoma: It also inhibits the growth of NPC cells, and its efficacy is comparable to cisplatin in vivo without its associated toxicity by inhibiting the STAT3 and PI3K/AKT/mTOR signaling pathways (68–70) and activating the caspase signaling pathway.